Alkermes plc showed that proteins delivered with its AIR inhalation technology were as efficacious as injectable proteins. Spinout Civitas Therapeutics Inc. is now using the same technology to improve the efficacy of small molecules over marketed oral or injectable counterparts.

Last week, Civitas started a Phase IIa trial of CVT-301, an inhaled levodopa to treat motor fluctuations associated with Parkinson's disease.